Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

70.14 +10.76 (+18.12%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Halozyme Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Critical Insights From Halozyme Therapeutics Analyst Ratings: What You Need To Know
Via Benzinga
NASDAQ:HALO is not too expensive for the growth it is showing.
NASDAQ:HALO is showing good growth, while it is not too expensive. 
Via Chartmill
NASDAQ:HALO is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
HALOZYME THERAPEUTICS INC (NASDAQ:HALO): good value for what you're paying. 
Via Chartmill
Top 2 Health Care Stocks That May Plunge In August
Via Benzinga
How Is The Market Feeling About Halozyme Therapeutics?
Via Benzinga
Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review
After Monday's panicked global sell-off, markets have calmed down. 
Via Investor's Business Daily
(HALO) - Analyzing Halozyme Therapeutics's Short Interest
Via Benzinga
Analyst Scoreboard: 14 Ratings For Halozyme Therapeutics
Via Benzinga
Looking for growth without the hefty price tag? Consider NASDAQ:HALO.
Investors should take note ofHALOZYME THERAPEUTICS INC (NASDAQ:HALO), a growth stock that remains attractively priced. 
Via Chartmill
Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation.
Why HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Is a Promising High-Growth Stock in the Midst of Consolidation. 
Via Chartmill
HALO Stock Earnings: Halozyme Therapeutics Beats EPS, Beats Revenue for Q2 2024
HALO stock results show that Halozyme Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Halozyme And Ligand — Two Leading Biotechs — Smash Quarterly Forecasts
Halozyme and Ligand beat second-quarter expectations late Tuesday. But only one of the biotech stocks jumped. 
Via Investor's Business Daily
Avadel Pharmaceuticals Stock Sees RS Rating Jump to 82
On Tuesday, Avadel Pharmaceuticals stock received a positive adjustment to its Relative Strength (RS) Rating, from 76 to 82. 
Via Investor's Business Daily
NASDAQ:HALO is probably undervalued for the fundamentals it is displaying.
When you look at HALOZYME THERAPEUTICS INC (NASDAQ:HALO), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
Will HALOZYME THERAPEUTICS INC Break Out? A Technical Analysis Perspective.
There are signs that NASDAQ:HALO may be ready to breakout. 
Via Chartmill
NASDAQ:HALO is showing good growth, while it is not too expensive.
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is not too expensive for the growth it is showing. 
Via Chartmill
What 13 Analyst Ratings Have To Say About Halozyme Therapeutics
Via Benzinga
3 Biotech Stocks on Track for 50% Returns (or More) by 2028
Investors should consider snapping up these high potential biotech stocks that could return 50% or more by 2028! 
Via InvestorPlace
Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark
On Friday, Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded to 82, up from 64 a day earlier. 
Via Investor's Business Daily
Beam Therapeutics Stock Earns RS Rating Jump To 85
On Wednesday, Beam Therapeutics stock now clears the 80 or higher Relative Strength Rating threshold, with a jump from 65 to 85. 
Via Investor's Business Daily
3 Biotech Stocks That Could Be Multibaggers in the Making: July Edition
These biotech stocks have promising outlooks that will bring major fortune to investors. Buy before it is too late. 
Via InvestorPlace
Biotech Arvinas Stock Earns 82 RS Rating
The Relative Strength (RS) Rating for Arvinas stock entered a new percentile Wednesday, with a rise from 62 to 82. 
Via Investor's Business Daily
Denali Therapeutics Stock Gets Technical Rating Upgrade
Denali Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating 
Via Investor's Business Daily
NASDAQ:HALO qualifies as a high growth stock and is consolidating.
HALOZYME THERAPEUTICS INC (NASDAQ:HALO): a strong growth stock preparing for the next leg up?. 
Via Chartmill
NASDAQ:HALO Shows Potential for a Breakout.
Will HALOZYME THERAPEUTICS INC Break Out? A Technical Analysis Perspective. 
Via Chartmill
3 Biotech Stocks to Buy Now: Q3 Edition
Biotech stocks to buy can be a strong portfolio addition due to their capability for rapid growth within an evolving industry. 
Via InvestorPlace
NASDAQ:HALO appears to be flying under the radar despite its strong fundamentals.
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is probably undervalued for the fundamentals it is displaying. 
Via Chartmill
3 Highly Rated Biotech Stocks for Your July Buy List
Discover three top-rated biotech stocks that are pushing forward the pharma and biotech revolution on Wall Street. 
Via InvestorPlace
3 Breakout Biotech Stocks on Track to Double by 2032
The tech sector has been at the forefront of the market rally in 2024. Consider these breakout biotech stocks as a great way to diversify. 
Via InvestorPlace
UroGen Pharma Stock Earns 91 RS Rating
UroGen Pharma stock had its Relative Strength (RS) Rating upgraded to 91 Thursday, up from 87 a day earlier. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.